Présentation de l'entreprise
Alphatec Holdings, Inc., operating under the ticker ATEC, functions as a medical technology enterprise dedicated to the design, development, and advancement of technologies for the surgical treatment of spinal disorders across the United States and international markets. Within the broader Healthcare sector, the company specifically occupies the Medical Devices industry, a domain characterized by high regulatory standards and significant capital investment in research and product innovation. The organization employs a workforce of 913 individuals and maintains a total market capitalization of $1.76 billion, while generating annual revenues of $764.16 million. These financial figures position the entity as a significant player in the spinal instrumentation space, indicating substantial scale in operations and product distribution despite the specialized nature of the medical device market.
Santé financière
The company reported revenue of $764.16 million over the trailing twelve months, yet it recorded a net income of -$143.358 million, revealing a substantial gap between top-line growth and profitability that highlights a strained cost structure or significant one-time expenses impacting the bottom line. Despite the negative net income, the enterprise generated positive EBITDA of $19.53 million, suggesting that core operational cash generation remains intact before financing and non-operating costs are deducted. The business demonstrated a free cash flow of $56.15 million, which provides a critical buffer for financial flexibility, allowing management to pursue strategic initiatives or manage working capital without immediate reliance on external financing. Analyzing the profitability metrics, the gross margin stands at 69.6%, reflecting efficient manufacturing and pricing power, whereas the operating margin is -2.5% and the profit margin is -18.8%, indicating that operating expenses and other costs are currently eroding a significant portion of gross profits. In terms of leverage, the company holds $160.81 million in cash against $596.09 million in debt, resulting in a debt-to-equity ratio of 1654.48, which signifies a highly leveraged balance sheet where equity is a relatively small base compared to the debt burden. Liquidity is supported by a current ratio of 2.06, indicating that current assets are more than double current liabilities, suggesting adequate short-term solvency to meet obligations as they fall due. Return metrics further illustrate the financial stress, with a Return on Equity of -630.7% and a Return on Assets of -4.6%, revealing that management effectiveness in generating returns on the capital base is currently negative.
Évaluation de la valorisation
Valuation multiples for Alphatec Holdings present a complex picture, as the P/E Ratio (TTM) is listed as N/A due to the lack of earnings, while the Forward P/E is 21.19, implying that the market expects a trajectory of normalized earnings growth to justify the current stock price in the future. The Price to Book ratio is elevated at 140.48, suggesting that the market values the company at a significant premium over its tangible book value, a common characteristic for asset-light medical device firms with high intangible assets or growth potential. Alternative valuation metrics provide additional context, with a Price to Sales ratio of 2.31 and an EV/EBITDA of 113.88, which indicates that investors are pricing the stock based on revenue multiple and earnings power relative to enterprise value rather than traditional earnings multiples. The stock has exhibited significant volatility within its trading range, with a 52-Week High of $23.29 and a 52-Week Low of $8.81. Given the current market dynamics and the wide spread between these extremes, the stock's position relative to this range fluctuates, but the wide band itself underscores the speculative nature of the investment. The Beta of 1.12 indicates that the share price is more volatile than the broader market, moving with greater intensity than the S&P 500 index during periods of market stress or rally.
Growth & Income
The company achieved a Revenue Growth (YoY) of 20.4%, demonstrating robust top-line expansion, while the Earnings Growth (YoY) is N/A due to the reported net loss, implying that earnings are currently lagging behind revenue growth as profitability has not yet materialized at scale. Regarding income distribution, the company has a Dividend Yield of N/A and a Payout Ratio of 0.0%, confirming that it does not distribute dividends to shareholders. Consequently, the company reinvests its entire earnings stream, including the positive free cash flow, back into the business to fund operations, research, and development rather than paying out cash to investors. This growth-focused strategy prioritizes capital allocation toward expanding market share and technological advancement over immediate shareholder returns, which is typical for high-growth medical device companies in their expansion phase.